Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$26.51 USD
-0.14 (-0.53%)
Updated Sep 19, 2025 10:52 AM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PCRX 26.51 -0.14(-0.53%)
Will PCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings
Pacira (PCRX) Tops Q2 Earnings Estimates
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for PCRX
Is PCRX poised for gains? Crossed Above 20 Day Moving Average shows up after advancing 2.22%
Fell Below 20 Day Moving Average appears for PCRX after 1.66% move
NR7 appears for PCRX after 1.3% move
20 Day Moving Average Support appears for PCRX after 0.96% move
The technical outlook for PCRX is unchanged after it rises 0.33% on September 12